Table.1 Clinical characteristics of the recruited major depressive disorder patients and healthy controls

From: Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents

Characteristics

Drug-naive MDD

Drug-treated MDDd

Healthy controls

P-value

Patients (n)

52

32

50

—

Male (n, %) a

27 (51.9%)

15 (46.9%)

27 (54.0%)

0.818

Age (years)

 Range

9–18

11–18

7–18

—

 Mean±SD b

15.79±2.56

15.88±1.96

15.54±2.51

0.789

BMI (kg/m2)

 Mean±SD b

19.61±2.27

19.95±2.47

19.76±1.71

0.582

Depression symptoms severity c

 HAMD-17 (Mean±SD)

22.50±3.63

21.36±2.99

NA

0.231

 CDRS-R (Mean±SD)

46.56±6.56

52.20±7.45

NA

0.080

Duration of illness (months) c

 Median, IQR

8.55 (4.28–15.63)

12.80 (6.40–19.20)

NA

0.970

Duration of antidepressant treatment (weeks)

 Median, IQR

NA

3.79 (2.12–7.52)

NA

 

Types of antidepressants (n, %)

 Fluvoxamine

NA

10 (31.3%)

NA

—

 Fluoxetine

NA

5 (15.6%)

NA

—

 Sertraline

NA

5 (15.6%)

NA

—

 Escitalopram

NA

4 (12.5%)

NA

—

 Paroxetine

NA

2 (6.3%)

NA

—

 Others

NA

6 (18.7%)

NA

—

  1. Continuous variables are expressed as Mean±Standard Deviation (SD) or Median with Interquartile Range (IQR)
  2. BMI Body Mass Index, CDRS-R Children’s Depression Rating Scale-Revised, HAMD-17 Hamilton Depression Scale (17-Items), MDD Major Depressive Disorder
  3. aAnalyzed by the Chi-square test
  4. bAnalyzed by the ANOVA followed by post hoc comparison of the groups using the Bonferroni test
  5. cAnalyzed by Mann-Whitney U test
  6. dAll drug-treated MDD patients were receiving their first antidepressant
Back to article page